Period:
Draw Mode:
| Volume | 100,578 |
|
|||||
| News | - | ||||||
| Day High | 0.760051 | Low High |
|||||
| Day Low | 0.7201 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| VolitionRX Limited | VNRX | AMEX | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.02 | -2.67% | 0.73 | 13:09:59 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.741 | 0.7201 | 0.760051 | 0.75 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 182 | 100,578 | $ 0.7429338 | $ 74,723 | - | 0.6265 - 2.7399 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 13:11:01 | 14 | $ 0.72 | USD |
VolitionRX Limited Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 57.04M | 78.14M | - | 306k | -30.27M | -0.39 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
VolitionRX News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VNRX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.07 | 1.095 | 0.6265 | 0.7318551 | 538,380 | -0.34 | -31.78% |
| 1 Month | 1.24 | 1.38 | 0.6265 | 0.9089339 | 220,770 | -0.51 | -41.13% |
| 3 Months | 1.41 | 1.55 | 0.6265 | 1.14 | 169,059 | -0.68 | -48.23% |
| 6 Months | 1.65 | 2.10 | 0.6265 | 1.39 | 144,843 | -0.92 | -55.76% |
| 1 Year | 1.50 | 2.7399 | 0.6265 | 1.71 | 143,943 | -0.77 | -51.33% |
| 3 Years | 3.13 | 6.67 | 0.6265 | 3.04 | 161,393 | -2.40 | -76.68% |
| 5 Years | 2.44 | 7.69 | 0.6265 | 3.37 | 176,449 | -1.71 | -70.08% |
VolitionRX Description
| VolitionRX Ltd is a us-based multi-national life sciences company. It is engaged in developing easy to use blood-based tests to accurately diagnose a range of cancers. The development pipeline includes assays to be used for symptomatic patients or asymptomatic populations. The company has developed more than 30 blood-based assays to detect specific biomarkers. It also develops Nucleosomics tests for several major cancers including CRC, pancreatic, lung and aggressive prostate. In addition, the company engages in the process of developing HyperGenomics tissue and blood-based tests to determine disease subtype following initial diagnosis and to help decide the appropriate therapy. |